Acuitive Technologies Receives FDA 510(k) Clearance for CITREPORE™, A New Synthetic Bioactive Bone Void Filler for Orthopedic Procedures
ALLENDALE, N.J., Nov. 12, 2024 — Acuitive Technologies, Inc. today announced it has received 510 clearance from the U.S. Food and Drug Administration to market CITREPORE, a unique synthetic bioactive bone void filler, using their patented CITREGEN® biomaterial technology. Following placement in a bony void, CITREPORE is resorbed predictably and replaced by the patient’s bone, providing Citrate